| ANTIRETROVIRAL DRUGS & DRUG CLASSES: FREQUENT/SEVERE SIDE EFFECTS i |
|
Skin |
Digestive |
Liver |
CV |
Musculo-skeletal |
Genitouri-nary |
Nervous |
Body fat |
Metabolic |
Other |
| NRTI |
| ZDV |
Nail pig-mentation |
Nausea |
Steatosis |
|
Myopathy |
|
|
Lipoatrophy |
Dyslipidaemia, Hyperlactataemia |
Anemia |
| d4T |
|
Pancreatitis |
Steatosis |
|
|
|
Peripheral neuropathy |
Lipoatrophy |
Dyslipidaemia |
|
| Hyperlactataemia |
| ddI |
|
Pancreatitis |
Steatosis, Liver fibrosis |
IHD |
|
|
Peripheral neuropathy |
|
Hyperlactataemia |
|
| 3TC |
|
|
|
|
|
|
|
|
|
|
| FTC |
|
|
|
|
|
|
|
|
|
|
| ABC |
Rash * |
|
|
IHD |
|
|
|
|
|
*: Systemic Hypersensitivity
(HLA B*5701 dependent) |
| TDF |
|
|
|
|
↓ BMD, Osteomalacia |
↓ GFR,
Fanconi syndrome |
|
|
|
|
| NNRTI |
| EFV |
Rash |
|
Hepatitis |
|
|
|
Depression, Suicidal ideation, |
|
Dyslipidaemia |
Teratogenesis |
| Dizziness, Sleep disturbances |
Gynaecomastia |
| NVP |
Rash |
|
Hepatitis |
|
|
|
|
|
|
Systemic Hypersensitivity (CD4- and gender-dependent) |
| ETV |
Rash |
|
|
|
|
|
|
|
|
|
| PI |
| IDV |
Dry skin |
Nausea and diarrhoea ii |
Jaundice |
IHD |
|
Nephroli-thiasis |
|
↑abdominal fat |
Dyslipidaemia |
|
| Nail dystrophy |
Diabetes mellitus |
| SQV |
|
|
|
|
|
|
|
Dyslipidaemia |
|
| LPV |
|
|
IHD |
|
|
|
|
Dyslipidaemia |
|
| FPV |
Rash |
|
IHD |
|
|
|
|
Dyslipidaemia |
|
| ATV |
|
Jaundice |
|
|
Nephroli-thiasis |
|
|
Dyslipidaemia |
|
| DRV |
|
|
|
|
|
|
|
Dyslipidaemia |
|
| TPV |
|
Hepatitis |
|
|
|
Intracranial haemorrhage |
|
Dyslipidaemia |
|
| FUSION INHIBITORS |
| ENF |
Injection
site reactions |
|
|
|
|
|
|
|
|
Hypersensitivity, ↑risk for pneumonia |
| INTEGRASE INHIBITORS |
| RAL |
|
Nausea |
|
|
Myopathy |
|
Headache |
|
|
|
| CCR5 INHIBITORS |
| MVC |
|
|
Hepatitis |
IHD |
|
|
|
|
|
↑risk for infections |
|
| i |
“Severe events” (events that can put patient’s life at risk and represent a medical emergency) are marked in bold letters. “Frequent events” (events expected in at least 10% of treated patients) are marked in red. Background knowledge on tolerability of ENF, DRV, ETV, RAL, and MVC is limited because of its recent introduction into the clinical armamentarium. |
| ii |
Frequency and severity differs between individual agents. |
|
|
|
